Banco de Sabadell S.A bought a new stake in Humana Inc (NYSE:HUM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 28,523 shares of the insurance provider’s stock, valued at approximately $7,075,000. Humana accounts for 0.9% of Banco de Sabadell S.A’s investment portfolio, making the stock its 24th biggest position.
Other large investors have also bought and sold shares of the company. Fieldpoint Private Securities LLC purchased a new stake in Humana in the third quarter valued at $115,000. American Beacon Advisors Inc. purchased a new stake in Humana in the fourth quarter valued at $122,000. ClariVest Asset Management LLC purchased a new stake in Humana in the third quarter valued at $144,000. YorkBridge Wealth Partners LLC raised its position in Humana by 99.0% in the fourth quarter. YorkBridge Wealth Partners LLC now owns 597 shares of the insurance provider’s stock valued at $159,000 after purchasing an additional 297 shares during the period. Finally, Daiwa SB Investments Ltd. raised its position in Humana by 44.9% in the fourth quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock valued at $176,000 after purchasing an additional 220 shares during the period. Institutional investors own 96.36% of the company’s stock.
Shares of HUM stock opened at $273.60 on Wednesday. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $37,550.64, a price-to-earnings ratio of 16.40, a P/E/G ratio of 1.48 and a beta of 0.95. Humana Inc has a 1-year low of $203.48 and a 1-year high of $293.35.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.06. Humana had a return on equity of 16.13% and a net margin of 4.55%. The company had revenue of $13.19 billion for the quarter, compared to the consensus estimate of $13.14 billion. During the same quarter in the prior year, the business earned $2.34 EPS. Humana’s revenue was up 2.4% on a year-over-year basis. research analysts forecast that Humana Inc will post 13.81 earnings per share for the current fiscal year.
Humana announced that its Board of Directors has authorized a stock buyback program on Thursday, December 14th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the insurance provider to buy shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.
The business also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be issued a dividend of $0.50 per share. This is an increase from Humana’s previous quarterly dividend of $0.40. The ex-dividend date is Wednesday, March 28th. This represents a $2.00 annualized dividend and a yield of 0.73%. Humana’s dividend payout ratio is 9.59%.
In other Humana news, SVP Brian P. Leclaire sold 1,679 shares of the company’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $245.97, for a total transaction of $412,983.63. Following the sale, the senior vice president now owns 9,888 shares in the company, valued at approximately $2,432,151.36. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Bruce D. Broussard sold 14,075 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $274.32, for a total value of $3,861,054.00. Following the sale, the chief executive officer now owns 113,896 shares in the company, valued at approximately $31,243,950.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,339 shares of company stock worth $9,081,201. 0.60% of the stock is owned by company insiders.
A number of equities research analysts have commented on HUM shares. Cantor Fitzgerald restated a “hold” rating and issued a $230.00 target price on shares of Humana in a research report on Tuesday, December 5th. Cowen restated a “buy” rating and issued a $285.00 target price on shares of Humana in a research report on Wednesday, December 13th. ValuEngine downgraded Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Goldman Sachs assumed coverage on Humana in a research report on Wednesday, January 3rd. They issued a “buy” rating and a $305.00 target price on the stock. Finally, Jefferies Group upgraded Humana from a “hold” rating to a “buy” rating and set a $221.00 price objective on the stock in a report on Friday, January 12th. Eight investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $270.47.
TRADEMARK VIOLATION WARNING: “Banco de Sabadell S.A Invests $7.08 Million in Humana Inc (HUM) Stock” was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thestockobserver.com/2018/03/21/banco-de-sabadell-s-a-invests-7-08-million-in-humana-inc-hum-stock.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.